| scholarly article | Q13442814 |
| P50 | author | Victoria R Polonis | Q89151700 |
| Cynthia A Derdeyn | Q94562588 | ||
| Elwyn Chomba | Q108185341 | ||
| Kelli Greene | Q114434977 | ||
| Salim Abdool Karim | Q18161438 | ||
| Bette Korber | Q30505218 | ||
| Carolyn Williamson | Q70376235 | ||
| Lynn Morris | Q70377150 | ||
| Koleka Mlisana | Q46535610 | ||
| Beatrice H. Hahn | Q55293537 | ||
| Jesus F Salazar-Gonzalez | Q57415418 | ||
| David C. Montefiori | Q63302725 | ||
| P2093 | author name string | Ming Zhang | |
| Ming Li | |||
| Feng Gao | |||
| Yingying Li | |||
| James E Robinson | |||
| Kunxue Hong | |||
| Susan Allen | |||
| Eric Hunter | |||
| Joseph Mulenga | |||
| Julie M Decker | |||
| Cheswa Vwalika | |||
| Maria G Salazar | |||
| Miroslawa Bilska | |||
| Jintao Zhou | |||
| P2860 | cites work | Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein | Q74029048 |
| Urgently needed: a filter for the HIV-1 vaccine pipeline | Q80402867 | ||
| The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan | Q21563445 | ||
| Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission | Q22241902 | ||
| Genotypic and phenotypic characterization of HIV-1 patients with primary infection | Q22242245 | ||
| The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 | ||
| A new classification for HIV-1 | Q22251292 | ||
| CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice | Q24286950 | ||
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| The neighbor-joining method: a new method for reconstructing phylogenetic trees | Q25939010 | ||
| Confidence Limits on Phylogenies: an Approach using the Bootstrap | Q26778379 | ||
| Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates | Q27489000 | ||
| Antibody domain exchange is an immunological solution to carbohydrate cluster recognition | Q27641517 | ||
| Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion | Q27641682 | ||
| A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences | Q27860580 | ||
| Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. | Q28217208 | ||
| Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B | Q28469023 | ||
| CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization | Q28646881 | ||
| A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding | Q28646883 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS | Q29614260 | ||
| Fast and sensitive multiple sequence alignments on a microcomputer | Q29618252 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. | Q29622903 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines | Q33780524 | ||
| Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. | Q33780595 | ||
| Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels | Q33780649 | ||
| Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys | Q33785114 | ||
| Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. | Q33794954 | ||
| Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. | Q33816465 | ||
| Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants | Q33850415 | ||
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
| Understanding the genetic diversity of HIV-1. | Q34087006 | ||
| Diversity considerations in HIV-1 vaccine selection | Q34136023 | ||
| Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein | Q34301897 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa | Q34332009 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response | Q34357078 | ||
| Prospects for vaccine protection against HIV-1 infection and AIDS. | Q34542236 | ||
| Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 | Q34648079 | ||
| The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. | Q34781878 | ||
| Defining the Protective Antibody Response for HIV-1 | Q35109054 | ||
| Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding | Q35845976 | ||
| Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. | Q35853750 | ||
| Multiple aligned sequence editor (MASE) | Q67269453 | ||
| A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A | Q68536789 | ||
| Sexual behavior of HIV discordant couples after HIV counseling and testing | Q73149539 | ||
| Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120 | Q73824497 | ||
| Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent i | Q35853761 | ||
| Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. | Q35857331 | ||
| Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop | Q35893615 | ||
| Change in coreceptor use correlates with disease progression in HIV-1--infected individuals | Q36376800 | ||
| Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization | Q36380741 | ||
| Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 | ||
| Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein | Q36549382 | ||
| Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization | Q36635390 | ||
| Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection | Q36647820 | ||
| Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41 | Q36694013 | ||
| Genital tract reservoirs | Q37446855 | ||
| Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer | Q38359871 | ||
| Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India | Q38935437 | ||
| Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. | Q38943221 | ||
| The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection | Q38949380 | ||
| Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication | Q39485916 | ||
| Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group | Q39547647 | ||
| Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected i | Q39549660 | ||
| CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. | Q39605077 | ||
| Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. | Q40191379 | ||
| Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum | Q40538332 | ||
| Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains | Q40621073 | ||
| Characterization and selection of HIV-1 subtype C isolates for use in vaccine development | Q40663802 | ||
| Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | Q40682865 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. | Q40832863 | ||
| CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. | Q41151327 | ||
| Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. | Q41276031 | ||
| A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. | Q41419602 | ||
| An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization | Q43451743 | ||
| HIV-1: nature's master of disguise | Q44031352 | ||
| Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group | Q45752018 | ||
| Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev | Q45771982 | ||
| HIV-1 genomic RNA diversification following sexual and parenteral virus transmission | Q45873185 | ||
| HIV vaccine design and the neutralizing antibody problem | Q46474020 | ||
| Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission | Q47878972 | ||
| A role for carbohydrates in immune evasion in AIDS. | Q47982875 | ||
| Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa | Q48332662 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Southern Africa | Q27394 |
| P304 | page(s) | 11776-11790 | |
| P577 | publication date | 2006-09-13 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | |
| P478 | volume | 80 |
| Q33547451 | 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms |
| Q33911247 | A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients |
| Q33653774 | A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays |
| Q36171938 | A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies |
| Q41930708 | A single gp120 residue can affect HIV-1 tropism in macaques. |
| Q36397434 | A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection |
| Q36247783 | A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006. |
| Q92111662 | AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region |
| Q35076897 | Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells |
| Q37037808 | An HIV/AIDS Prophylactic vaccine is possible |
| Q34540222 | An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials |
| Q33526340 | Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals |
| Q40147993 | Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis |
| Q28752503 | Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q36141515 | Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q42738983 | Antibody-based HIV-1 vaccines: recent developments and future directions |
| Q39124318 | Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection. |
| Q37547245 | Antigenic properties of the HIV envelope on virions in solution |
| Q27320687 | Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells |
| Q35689392 | Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors |
| Q30375834 | Appreciating HIV type 1 diversity: subtype differences in Env. |
| Q28751926 | Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys |
| Q36171833 | B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. |
| Q34597300 | Back to the future: covalent epitope-based HIV vaccine development |
| Q46226616 | Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. |
| Q40063752 | Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. |
| Q34057606 | Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study |
| Q35689608 | Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions |
| Q35774051 | Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site |
| Q33614495 | Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables |
| Q56974226 | Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? |
| Q37139889 | Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions |
| Q37300360 | CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo |
| Q21090521 | CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics |
| Q34545420 | CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors |
| Q44176443 | Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection |
| Q100430434 | Characteristics of HIV-1 env genes from Chinese chronically infected donors with highly broad cross-neutralizing activity |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q35914362 | Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. |
| Q34620235 | Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users |
| Q37252913 | Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys |
| Q34300812 | Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection |
| Q35140429 | Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry |
| Q39186163 | Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies |
| Q28749755 | Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies |
| Q33648910 | Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes |
| Q90343014 | Comparison of the antiviral activity of the microbicide candidate griffithsin and its tandemers derivatives against different modes of HIV-1 transmission |
| Q36978861 | Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design |
| Q34471962 | Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene |
| Q44106801 | Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China |
| Q41610618 | Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains |
| Q33603702 | Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women |
| Q92136034 | Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure |
| Q37153097 | Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms |
| Q28554907 | Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene |
| Q34204047 | Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. |
| Q36319309 | Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library |
| Q37445549 | Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins |
| Q36528901 | Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers |
| Q42554027 | Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers |
| Q37256644 | Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1 |
| Q27666159 | Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41 |
| Q27662167 | Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 |
| Q43004709 | Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41. |
| Q36102994 | Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens |
| Q34094476 | Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies |
| Q38737604 | Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity. |
| Q27671182 | Designed oligomers of cyanovirin-N show enhanced HIV neutralization |
| Q35903806 | Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells |
| Q41933100 | Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells |
| Q36736392 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques |
| Q35774679 | Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis |
| Q42850455 | Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity |
| Q37644030 | Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. |
| Q36194234 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth |
| Q37238727 | Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrin |
| Q36000736 | Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape |
| Q92772993 | Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo |
| Q36785795 | Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides |
| Q34594701 | Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1 |
| Q35666057 | Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins |
| Q37547162 | Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains |
| Q33313394 | Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. |
| Q36740547 | Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. |
| Q35076987 | Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected |
| Q42959357 | Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. |
| Q33504599 | Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways |
| Q33558696 | Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents |
| Q36177537 | Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine |
| Q24653373 | Evolution of proviral gp120 over the first year of HIV-1 subtype C infection |
| Q56930898 | Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women |
| Q36802333 | Exploiting the defensive sugars of HIV-1 for drug and vaccine design |
| Q92668726 | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| Q35828002 | Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization |
| Q36081789 | Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization |
| Q37033269 | Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies |
| Q55356257 | Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. |
| Q33749206 | Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission |
| Q33558279 | Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1 |
| Q36827168 | Generation of lineage-related, mucosally transmissible subtype C R5 simian-human immunodeficiency viruses capable of AIDS development, induction of neurological disease, and coreceptor switching in rhesus macaques |
| Q43611862 | Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies |
| Q37305864 | Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality |
| Q37273158 | Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection |
| Q33719511 | Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies |
| Q35289861 | Genotypic and functional properties of early infant HIV-1 envelopes |
| Q34392963 | Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies |
| Q36294701 | Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C. |
| Q34555891 | Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity |
| Q39824069 | Glycosylation site-specific analysis of clade C HIV-1 envelope proteins |
| Q90701830 | Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126 |
| Q36526615 | HIV transmission |
| Q36269097 | HIV transmission biology: translation for HIV prevention |
| Q35173635 | HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies |
| Q37851950 | HIV vaccines: progress to date. |
| Q47547483 | HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees |
| Q33680752 | HIV-1 Populations in Semen Arise through Multiple Mechanisms |
| Q28647225 | HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers |
| Q37360774 | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
| Q35826271 | HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes |
| Q27000480 | HIV-1 neutralizing antibodies: understanding nature's pathways |
| Q35216488 | HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages |
| Q36334990 | HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection |
| Q21090490 | HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response |
| Q34158525 | HIV-1 transmission biology: selection and characteristics of infecting viruses |
| Q39402539 | HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes |
| Q33812812 | Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant |
| Q37275049 | Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. |
| Q35940070 | High throughput functional analysis of HIV-1 env genes without cloning |
| Q37157729 | High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia |
| Q35826509 | High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection |
| Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
| Q36423897 | Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection |
| Q36994644 | Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses |
| Q44578912 | Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines |
| Q36171536 | Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. |
| Q35914382 | Identification of Owl Monkey CD4 Receptors Broadly Compatible with Early-Stage HIV-1 Isolates |
| Q34428738 | Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. |
| Q34441074 | Illuminating HIV gp120-Ligand Recognition through Computationally-Driven Optimization of Antibody-Recruiting Molecules. |
| Q35171701 | Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization |
| Q34164923 | Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies |
| Q28535477 | Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone |
| Q34593647 | Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies |
| Q36978467 | Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy |
| Q34009730 | In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies |
| Q34042758 | Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting |
| Q33912373 | Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual |
| Q28743608 | LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays |
| Q37362368 | Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection |
| Q34206171 | Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. |
| Q33374701 | Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 |
| Q35077797 | Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies |
| Q34792976 | Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. |
| Q34157802 | Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine |
| Q36107520 | Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin |
| Q37410770 | Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment |
| Q40290511 | Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. |
| Q42241364 | Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling |
| Q30376865 | Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus |
| Q92147755 | Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses |
| Q35129224 | Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus |
| Q30368471 | Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. |
| Q36099045 | N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization |
| Q34109778 | Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. |
| Q34304203 | Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. |
| Q30537665 | Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China |
| Q47562235 | Neutralization tiers of HIV-1. |
| Q33382060 | Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection |
| Q35208657 | Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination |
| Q33887693 | Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? |
| Q37519312 | Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? |
| Q35857268 | Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection |
| Q34637968 | Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins |
| Q27021279 | Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus |
| Q41925528 | Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry |
| Q38659318 | Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments |
| Q47109778 | Patterns of conserved gp120 epitope presentation on attached HIV-1 virions |
| Q36281817 | Phenotypic Correlates of HIV-1 Macrophage Tropism |
| Q35192915 | Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins |
| Q30402036 | Phylogenetic structure in African HIV-1 subtype C revealed by selective sequential pruning |
| Q36694846 | Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q36588632 | Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants |
| Q34284855 | Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization |
| Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
| Q89592396 | Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation |
| Q30374995 | Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. |
| Q34551010 | Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate |
| Q35160124 | Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q33640144 | R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models |
| Q34540352 | Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. |
| Q34539819 | Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs |
| Q92288781 | Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector |
| Q30657338 | Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth |
| Q36977750 | Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine |
| Q36155365 | Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses |
| Q36837815 | Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization |
| Q34357068 | Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. |
| Q33961704 | Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. |
| Q39723388 | Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization |
| Q24650458 | Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component |
| Q41933070 | Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines |
| Q37370674 | Selection of HIV variants with signature genotypic characteristics during heterosexual transmission |
| Q40076041 | Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers |
| Q64979797 | Selective use of primate CD4 receptors by HIV-1. |
| Q58598623 | Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time |
| Q36132706 | Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. |
| Q36634965 | Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes |
| Q39455602 | Single-chain Fv-based anti-HIV proteins: potential and limitations |
| Q37084521 | Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses |
| Q37510603 | Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q36138144 | Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens |
| Q90438646 | Stoichiometric Analyses of Soluble CD4 to Native-like HIV-1 Envelope by Single-Molecule Fluorescence Spectroscopy |
| Q27660384 | Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity |
| Q36364955 | Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity |
| Q27678493 | Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors |
| Q59359981 | Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120 |
| Q90212036 | Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes |
| Q35947805 | Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies |
| Q59351886 | Synthesis, Antiviral Activity, and Structure-Activity Relationship of 1,3-Benzodioxolyl Pyrrole-Based Entry Inhibitors Targeting the Phe43 Cavity in HIV-1 gp120 |
| Q33664910 | Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response |
| Q27000889 | The Antibody Response against HIV-1 |
| Q40091554 | The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards |
| Q26786540 | The HIV glycan shield as a target for broadly neutralizing antibodies |
| Q35973578 | The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment. |
| Q34982698 | The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection |
| Q36483346 | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection |
| Q30367176 | The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. |
| Q37283747 | The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes. |
| Q35140408 | The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population |
| Q37036454 | The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism |
| Q37667754 | The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. |
| Q37333734 | The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity |
| Q35743210 | The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells |
| Q40144203 | The mutable vaccine for mutable viruses |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q34017550 | The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. |
| Q37547702 | The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. |
| Q33614365 | Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies |
| Q36000722 | Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7 |
| Q33826682 | Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain |
| Q35943810 | UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C |
| Q41932027 | Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes |
| Q37256661 | Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. |
| Q27332360 | Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection |
| Q42204816 | Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. |
| Q58591002 | Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones |
| Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
| Q27676728 | Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth |
| Q37240053 | Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. |
| Q37333754 | Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype |
| Q38936957 | Vpx complementation of 'non-macrophage tropic' R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages. |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
| Q33348658 | sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates |
Search more.